Skip Navigation LinksHome > February 2015 - Volume 38 - Issue 1 > Lenalidomide for Second-line Treatment of Advanced Hepatocel...
Text sizing:
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3182868c66
Original Articles: Gastrointestinal

Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: A Brown University Oncology Group Phase II Study

Safran, Howard MD*; Charpentier, Kevin P. MD*; Kaubisch, Andreas MD; Mantripragada, Kalyan MD, MPH*; Dubel, Gregory MD*; Perez, Kimberly MD*; Faricy-Anderson, Katherine MD*; Miner, Thomas MD*; Eng, Yoko ANP; Victor, Joel MD; Plette, Angela MD*; Espat, Joseph MD*; Bakalarski, Pamela CCRP, MPA*; Wingate, Patti BS*; Berz, David MD*; Luppe, Denise BSN*; Martel, Diane RN*; Rosati, Kayla EdM*; Aparo, Santiago MD

Collapse Box


Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib.

Materials and Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities.

Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months.

Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.

© 2015 by Lippincott Williams & Wilkins, Inc


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.